Iniparib, the potential first-in-class poly (adenosine diphosphate-ribose) polymerase inhibitor, failed to meet the coprimary end point of overall and progression-free survival in a pivotal phase III study of women with metastatic triple-negative breast cancer, the company reported after market close Jan. 27.The results are particularly disappointing in light of stellar phase II findings presented at the San Antonio Breast Cancer Symposium in 2009 and published online Jan. 5 in the New England Journal...